UPLC Liquid Chromatograph Mass Spectrometer

描述（由申请人提供）：我们申请资金购买岛津LCMS-2020与UFLC XR的协作核心设施（有机化学核心中心或OCCC）在哥伦比亚大学医学中心（CMEC）。有机化学核心中心，包括其LC/MS设施，是唯一提供定制有机合成，药物发现和仪器分析服务的实体，以支持NIH资助的生物医学研究。该仪器将取代10岁的2010 A岛津液相色谱质谱仪，这一直在经历频繁的年龄相关和年龄适当的困难。如果不能及时更新到新的工具，就会危及大量赠款的进展。新的工具将使25个（每年平均）个人NIH赠款的持续支持。该仪器的主要“动手”用户将是该中心的合成有机化学家，他们通过生物医学研究人员在CMEC的合作努力来制造和表征小分子。该仪器的最终受益者，即指导合成化学家的研究人员，涵盖了从NIH资助数十年的成熟研究人员到首次寻求NIH支持的年轻教师的范围。他们的研究依赖于该中心的LC/MS设施表征的小分子，以研究与各种疾病状态相关的生物过程，如阿尔茨海默病，精神分裂症，前列腺癌和乳腺癌，心力衰竭，糖尿病，慢性疼痛和肺气肿等。该仪器将由医学系实验治疗学部内的有机化学核心机构和哥伦比亚大学医学中心（CMEC）欧文临床和转化研究所内的生物标志物核心机构共同管理。

DESCRIPTION (provided by applicant): We request funds to purchase a Shimadzu LCMS-2020 with UFLC XR for a collaborative core facility (The Organic Chemistry Core Center or OCCC) at the Columbia University Medical Center (CUMC). The Organic Chemistry Core Center, including its LC/MS facility, is the only entity offering custom organic synthesis, drug discovery, and instrumental analysis services in support of NIH-funded biomedical research at the CUMC. The instrument will replace a 10-year-old 2010A Shimadzu liquid chromatograph mass spectrometer, which has been experiencing frequent age-related and age-appropriate difficulties. Lack of timely upgrade to a new instrument endangers progress of a large number of grants. The new instrument will enable the continuing support for 25 (a yearly average) individual NIH grants. The primary "hands-on" users of the instrument will be synthetic organic chemists of the Center that make and characterize small molecules directed through a collaborative effort by biomedical researchers at the CUMC. The end beneficiaries of the instrument, that is, the researchers directing the synthetic chemists, span the spectrum from well-established investigators, funded by the NIH for decades, to young faculty, seeking first-time support from the NIH. Their research relies on small molecules characterized by the Center's LC/MS facility to study biological processes associated with various disease states, such as Alzheimer's Disease, schizophrenia, prostate and breast cancer, heart failure, diabetes, chronic pain, and emphysema, among others. The instrument will be co-managed by the Organic Chemistry Core Facility within the Division of Experimental Therapeutics of the Department of Medicine and the Biomarkers Core Facility within the Irving Institute for Clinical and Translational Research at the Columbia University Medical Center (CUMC).